In Partnership with NGeneBio

KT and NGeneBio researchers conduct experiment at NGeneBio’s research lab.

KT announced on Sept. 25 that it has signed a business agreement with NGeneBio to jointly develop and commercialize digital healthcare services based on genetic information analyses.

NGeneBio started as KT's first in-house venture startup specializing in R&D, reagent production, software R&D and precision diagnoses in the field of genes. Its next-generation sequencing (NGS) diagnostic products have been approved by the Ministry of Food and Drug Safety for the first time in Korea. Its breast cancer precision diagnosis reagents have become the first product from an Asian company to receive CE-IVD approval in Europe. With these proven track records, the company is entering the precision diagnosis technology sector.

Under this agreement, the two companies will combine KT's artificial intelligence, big data, and cloud capabilities with NGeneBio's expertise in genetic information analysis to jointly develop and commercialize services and platforms.

Major areas of cooperation include the development of personalized healthcare (food therapies and exercise therapies) services, the establishment of a specialized platform for storing and managing personal genetic analysis information, and the development of big data analysis services for genetic information.

KT is going to upgrade its genetic information analysis and storage management environment through cooperation with NGeneBio.

NGeneBio plans to provide KT customers with customized healthcare coaching services based on Genorhythm, a healthcare service that analyzes neutral fat, blood sugar and blood pressure.

Copyright © BusinessKorea. Prohibited from unauthorized reproduction and redistribution